Clinical Psychopharmacology and Neuroscience最新文献

{"title":"Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults.","authors":"Daeyoung Roh,&nbsp;Ki Won Jang,&nbsp;Chan-Hyung Kim","doi":"10.9758/cpn.23.1075","DOIUrl":"10.9758/cpn.23.1075","url":null,"abstract":"<p><p>In the present article, we provide a comprehensive review of the treatment strategies for obsessive-compulsive disorder (OCD), a common, chronic, and often debilitating disorder, characterized by overwhelming obsessions and compulsions. OCD typically starts in childhood or adolescence and persists throughout life, causing functional impairment across multiple domains. The article begins by describing the historical concepts of OCD from religious and guilt-based explanations to psychoanalytic perspectives, and then explores the changing understanding of OCD as a treatable condition. Recent advances include the development of evidence-based psychological treatments, such as exposure and response prevention, and pharmacological treatments, such as selective serotonin reuptake inhibitors. The latest version of the Diagnostic and Statistical Manual of Mental Disorders, and the International Classification of Diseases, has removed OCD from the anxiety disorder grouping and regrouped it into obsessive-compulsive and related disorders. We conclude by highlighting the current state of knowledge and development in the clinical management of OCD, including recommendations for first- and second-line treatments, alternative, or augmentative strategies for and novel agents under investigation for OCD. In future, the latest advances in neuroimaging, electrophysiology, digital technology, and data-driven analysis will help elucidate the pathophysiology of OCD and develop personalized intervention strategies.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/b4/cpn-21-4-676.PMC10591165.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47274483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between Vitamin B12 and Mental Health in Children and Adolescents: A Systematic Review and Meta-analysis.","authors":"Yongjun Tan,&nbsp;Li Zhou,&nbsp;Kaiqi Gu,&nbsp;Caihong Xie,&nbsp;Yuhan Wang,&nbsp;Lijun Cha,&nbsp;Youlin Wu,&nbsp;Jiani Wang,&nbsp;Xiaosong Song,&nbsp;Xia Chen,&nbsp;Hua Hu,&nbsp;Qin Yang","doi":"10.9758/cpn.22.1040","DOIUrl":"10.9758/cpn.22.1040","url":null,"abstract":"<p><p>To conduct the association between vitamin B12 and mental health in children and adolescents. Five databases were searched for observational studies in any language reporting on mental health and vitamin B12 levels or intake in children and adolescents from inception to March 18, 2022. Two authors independently extracted data and assessed study quality. Qualitative and quantitative analysis of data were performed. The review was registered in the PROSPERO database (CRD42022345476). Fifty six studies containing 37,932 participants were identified in the review. Vitamin B12 levels were lower in participants with autism spectrum disorders (ASD) (standardized mean difference [SMD], -1.61; 95% confidence interval [95% CI], -2.44 to -0.79; <i>p</i> ＜ 0.001), attention deficit hyperactivity disorders (SMD, -0.39; 95% CI, -0.78 to -0.00; <i>p</i> = 0.049) compared with control group. Vitamin B12 intake were lower in participants with ASDs (SMD, -0.86; 95% CI, -1.48 to -0.24; <i>p</i> = 0.006) compared with control group, but showed no difference between depression group (SMD, -0.06; 95% CI, -0.15 to 0.03; <i>p</i> = 0.17) and the control group. Higher vitamin B12 intake were associated with lower risk of depression (odds ratio [OR], 0.79; 95% CI, 0.63-0.98; <i>p</i> = 0.034) and behavioral problems (OR, 0.83; 95% CI, 0.69-0.99; <i>p</i> = 0.04). The vast majority of included studies supported potential positive influence of vitamin B12 on mental health, and vitamin B12 deficiency may be a reversible cause for some mental health disorders in children and adolescents.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/7f/cpn-21-4-617.PMC10591166.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41761174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acoustic and Subjective Basis of Emotional Perception in Comatose Patients: A Comparative Study.","authors":"Galina V Portnova,&nbsp;Elena V Proskurnina","doi":"10.9758/cpn.22.1028","DOIUrl":"10.9758/cpn.22.1028","url":null,"abstract":"<p><strong>Objective: </strong>: The acoustic stimulation in consciousness patients may improve the diagnosis assessment and the effectiveness of rehabilitation procedures. We aimed to investigate the event-related potential (ERP) response to emotional auditory stimuli in comatose patients.</p><p><strong>Methods: </strong>: We measured the nonlinear and linear electroencephalogram (EEG) features, prepared the acoustic analysis of stimuli parameters, and assessed the subjective emotional rates of stimuli characteristics.</p><p><strong>Results: </strong>: Patients with better outcomes had recognizable ERP responses and significant changes of the nonlinear EEG features to emotional sounds, unlike patients with worse outcomes. The response of comatose patients was attributed to acoustical features of emotional sounds, whereas the EEG response of healthy subjects was associated with their subjective feelings. The comatose patients demonstrated the variable EEG activity for neutral and emotional sounds.</p><p><strong>Conclusion: </strong>: Thus, the EEG reactivity followed the better outcome of comatose patients to emotional stimuli. The study assumed the substantial differences of emotional stimuli perception in the healthy and unconscious brain.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/1d/cpn-21-4-701.PMC10591159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49150378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Understanding on Psilocybin for Major Depressive Disorder: A Review Focusing on Clinical Trials","authors":"Sheng-Min Wang, Sunghwan Kim, Won-Seok Choi, Hyun Kook Lim, Y. Woo, C. Pae, W. Bahk","doi":"10.9758/cpn.23.1134","DOIUrl":"https://doi.org/10.9758/cpn.23.1134","url":null,"abstract":"","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139205649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peripheral Markers of Suicidal Behavior: Current Findings and Clinical Implications.","authors":"Hee-Ju Kang,&nbsp;Ju-Wan Kim,&nbsp;Sung-Wan Kim,&nbsp;Jung-Soo Han,&nbsp;In Kyoon Lyoo,&nbsp;Jae-Min Kim","doi":"10.9758/cpn.22.1046","DOIUrl":"10.9758/cpn.22.1046","url":null,"abstract":"<p><p>Biomarkers of suicidal behavior (SB), particularly peripheral biomarkers, may aid in the development of preventive and intervention strategies. The peripheral biomarkers of SB should be easily accessible, cost-effective, and minimally invasive. To identify peripheral biomarkers of SB, we summarized the current knowledge related to SB biomarkers with a focus on suicidal outcomes (suicidal ideation [SI], suicide risk [SR], suicide attempt [SA], and suicide death [SD]), measured site (center or periphery), and study design (cross-sectional or longitudinal). We also evaluated the central findings to validate the findings of peripheral biomarkers of SB. We found reduced peripheral interleukin (IL)-2 levels in individuals with a recent SA, higher cerebrospinal fluid (CSF) IL-6 levels in patients with a current SR and future SD, higher CSF tumor necrosis factor-α levels for current and future SRs, higher high-sensitivity C-reactive protein levels and lower peripheral total cholesterol levels for recent SAs, lower peripheral 5-HT levels for present SR, and a lower folate level for future SR and SA within 1 year. Previous studies have shown inconsistent associations of low peripheral leptin levels with SR and recent SA; therefore, further study is required. Given the multiple determinants of SB and weak associations with single biological markers, combinations of potential biological markers rather than single markers may improve the screening, diagnosis, and prediction of SB.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/60/28/cpn-21-4-650.PMC10591170.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41877593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher Levels of Galectin-1 and Galectin-3 in Young Subjects with Autism Spectrum Disorder Compared to Unaffected Siblings and Healthy Controls.","authors":"Zeynep Nur Karadogan, Yasar Tanir, Ali Karayagmurlu, Canan Kucukgergin, Murat Coskun","doi":"10.9758/cpn.23.1052","DOIUrl":"10.9758/cpn.23.1052","url":null,"abstract":"<p><strong>Objective: </strong>: Despite being highly genetic, the etiology of autism spectrum disorder (ASD), has not yet been clarified. Recent research has focused on the role of neuroinflammation and immune system dysfunction in the pathophysiology of neurodevelopmental disorders including ASD. Galectin-1 and galactin-3 are considered among the biomarkers of neuroinflammation and there has been recent reports on the potential role of galectins in the etiology of neurodevelopmental disorders. However, there has been no study examining the relationship between ASD and galectin levels.</p><p><strong>Methods: </strong>: Current study aimed to investigate galectin-1 and galectin-3 serum levels in young subjects with ASD comparing with their unaffected siblings and healthy controls.</p><p><strong>Results: </strong>: We found significantly higher levels of galectin-1 in case group compared to both unaffected siblings and healthy controls, and higher levels of galectin-3 in case group compared to healthy controls. However, there was no significant association between galectin-1 and galectin-3 levels with the severity of ASD.</p><p><strong>Conclusion: </strong>: Findings of our study may support neuroinflammation hypothesis in the etiology of ASD and the potential role of galectin-1 and galectin-3 as biomarkers.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/a8/cpn-21-4-749.PMC10591161.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Loudness Dependence of Auditory-evoked Potentials and Suicidality.","authors":"Youngjun Cho,&nbsp;Young-Min Park,&nbsp;Miseon Shim,&nbsp;Seung-Hwan Lee","doi":"10.9758/cpn.23.1050","DOIUrl":"10.9758/cpn.23.1050","url":null,"abstract":"<p><strong>Objective: </strong>: Serotonin concentration is associated with suicide in patients with major depressive disorder. Loudness dependence of auditory-evoked potentials (LDAEPs), a representative neurophysiological indicator, is related to serotonin activity. Therefore, this study aimed to investigate the relationship between LDAEPs and suicidal ideation, suicide attempts, and the severity of depression.</p><p><strong>Methods: </strong>: We evaluated the scalp N1, P2, and N1/P2 LDAEPs along with standardized low-resolution brain electromagnetic tomography (sLORETA)-localized N1, P2, and N1/P2 LDAEPs of 221 patients with major depressive disorder. The demographic and clinical data of the patients, including data on suicidal ideation and previous suicide attempts, were obtained from clinical interviews and medical records. The severity of depression was assessed using the Beck Depression Inventory and Hamilton Depression Rating Scale, whereas suicidal ideation was evaluated using the Beck Scale for Suicidal Ideation (BSS).</p><p><strong>Results: </strong>: The total BSS score was associated with low N1/P2 LDAEP (<i>p</i> = 0.045), whereas P2 sLORETA-LDAEP was associated with lower previous suicide attempts (<i>p</i> = 0.043). In addition, suicide attempt was correlated with an elevated P2 left sLORETA-LDAEP (coefficient = 4.638, <i>p</i> = 0.038).</p><p><strong>Conclusion: </strong>: These findings suggest that suicidal ideation is associated with decreased LDAEP, whereas suicide attempt is associated with increased LDAEP.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/0e/cpn-21-4-742.PMC10591167.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41318482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dextromethorphan-bupropion (Auvelity) for the Treatment of Major Depressive Disorder.","authors":"Brian McCarthy,&nbsp;Hannah Bunn,&nbsp;Morgan Santalucia,&nbsp;Charlotte Wilmouth,&nbsp;Andrew Muzyk,&nbsp;Colin M Smith","doi":"10.9758/cpn.23.1081","DOIUrl":"10.9758/cpn.23.1081","url":null,"abstract":"<p><p>Depression is a significant cause of morbidity and mortality globally. Although various pharmacologic options exist for depression, treatments are limited by delayed or incomplete therapeutic response, low rates of remission, and adverse effects necessitating effective, fast-acting, and better tolerated alternatives. The purpose of this review is to describe the safety and efficacy of dextromethorphan-bupropion (Auvelity), a Food and Drug Administration approved treatment for major depressive disorder in adults. Dextromethorphan modulates glutamate signaling through uncompetitive antagonism of N-methyl-D-aspartate receptors and sigma-1 agonism, while bupropion increases the bioavailability of dextromethorphan by CYP2D6 inhibition. In a phase 3 trial with dextromethorphan-bupropion 45-105 mg for patients with major depressive disorder saw significant reductions in their Montgomery-Åsberg Depression Rating Scale total scores compared to placebo. A phase 2 trial comparing dextromethorphan-bupropion 45-105 mg to bupropion monotherapy led to significant reduction in Montgomery-Åsberg Depression Rating Scale score. Changes in Montgomery-Åsberg Depression Rating Scale with dextromethorphan-bupropion were seen within two weeks in both clinical trials. Remission and response rates were significantly higher with dextromethorphan-bupropion in both studies. The medication was well-tolerated in both trials, with the most common adverse events being rated as mild-to-moderate. Two long-term, open-label studies with dextromethorphan-bupropion saw large reductions in Montgomery-Åsberg Depression Rating Scale scores that were maintained through 12 and 15 months of treatment. In both long-term studies, remission rates approached 70%, while response rates were greater than 80%. These data suggest that dextromethorphan-bupropion is an effective, fast-acting, and well tolerated option for depression treatment and produced remission in a large percentage of patients.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5c/3f/cpn-21-4-609.PMC10591164.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44137961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcranial Alternating Current Stimulation (tACS) and Its Role in Schizophrenia: A Scoping Review.","authors":"Harsh Pathak, Vanteemar S Sreeraj, Ganesan Venkatasubramanian","doi":"10.9758/cpn.22.1042","DOIUrl":"10.9758/cpn.22.1042","url":null,"abstract":"<p><p>Transcranial alternating current stimulation (tACS) may modulate neuronal oscillations by applying sinusoidal alternating current, thereby alleviating associated symptoms in schizophrenia. Considering its possible utility in schizophrenia, we reviewed the literature for tACS protocols administered in schizophrenia and their findings. A scoping review was conducted following the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guideline in databases and clinical trial registers. The search resulted in 59 publications. After excluding review articles unrelated to tACS, trials without published results or not involving patients with schizophrenia, 14 studies were included. Among the included studies/case reports only 5 were randomized controlled therapeutic trials. The studies investigated the utility of tACS for clinical and neurobiological outcomes. All studies reported good tolerability with only transient mild side effects. It was administered mostly during the working memory task (such as computerized n-back task, dual back task, and computerized digit symbol substitution task) for schizophrenia patients with cognitive deficits and during resting state while targeting positive symptoms. A possible reduction in hallucinations and delusions using alpha tACS, and improvement in negative and cognitive deficits with theta and gamma tACS were reported. Nevertheless, one of the randomized controlled trials targeting hallucinations was negative and rigorous large-sample studies are lacking for other domains. The current evidence for tACS in schizophrenia is preliminary though promising. In future, more sham controlled randomized trials assessing the effect of tACS on various domains are needed to substantiate these early findings.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":3.2,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9e/7e/cpn-21-4-634.PMC10591171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41683897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Comorbidities of Adult Attention-deficit/hyperactivity Disorder in a Community Sample from Korea.","authors":"Young Sup Woo, Jung Wan Hong, Se-Hoon Shim, Hyung Mo Sung, Jeong Seok Seo, Sung-Yong Park, Jung Goo Lee, Bo-Hyun Yoon, Won-Myong Bahk","doi":"10.9758/cpn.23.1112","DOIUrl":"10.9758/cpn.23.1112","url":null,"abstract":"<p><strong>Objective: </strong>: Attention-deficit/hyperactivity disorder (ADHD) is prevalent in adults, and psychiatric comorbidities are common in adults with ADHD. We aimed to examine the prevalence of adult ADHD with several common psychiatric conditions in a community sample in Korea and the association between adult ADHD and risk of psychiatric comorbidities.</p><p><strong>Methods: </strong>: This study used a cross-sectional survey design. We provided supplementary and optional self-report questionnaires, including the Korean version of the World Health Organization Adult ADHD Self-Report Scale (ASRS) short screening scale, Patient Health Questionnaire-9 for screening for depression, Alcohol Use Disorders Identification Test alcohol consumption questions, and the Korean version of the Mood Disorders Questionnaire, to Korean adults who visited one of six centers of a large private healthcare company for the National General Health Examination.</p><p><strong>Results: </strong>: A total of 17,799 subjects included in this study, and 430 (2.4%) were positive on the ASRS screen. ADHD was significantly associated with the 19-30-year-old age group (odds ratio [OR] = 3.938), lower income (OR = 1.298), depression (OR = 11.563), and bipolar disorder (OR = 3.162).</p><p><strong>Conclusion: </strong>: Adult ADHD was highly associated with depression and bipolar disorder, suggesting that clinicians should carefully evaluate and treat such psychiatric disorders in adults with ADHD symptoms.</p>","PeriodicalId":10420,"journal":{"name":"Clinical Psychopharmacology and Neuroscience","volume":null,"pages":null},"PeriodicalIF":2.4,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10591169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49685725","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}